Genetic Causes of Hypercholesterolaemia in the Emirati Population
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03597958|
Recruitment Status : Recruiting
First Posted : July 24, 2018
Last Update Posted : February 27, 2019
|Condition or disease||Intervention/treatment|
|Familial Hypercholesterolemia||Genetic: Next generation sequencing (NGS)|
Familial Hypercholesterolaemia is an inherited genetic disorder which causes elevated levels of low density lipoprotein (LDL) cholesterol in the blood. High LDL is a risk factor for with arterial disease and people with FH develop coronary artery disease (CAD) early in life. People with only one inherited copy of the defective gene usually develop CAD before the age of 60, whereas individuals who have inherited two copies usually die before the age of 30 from myocardial infarction ("heart attack") or sudden cardiac death. Coronary artery disease is a major cause of death and disability in the United Arab Emirates (UAE), and the medical costs associated with treating this condition are significant. Early identification and treatment of affected individuals can substantially postpone the onset of arterial disease and reduce the risk of mortality. In clinical practice, FH cases are usually identified by screening the relatives of people known to be affected.
Current study will focus on identifying individuals with high risk score for FH, based on the available medical records and laboratory information system (LIS). Furthermore, patients with history of premature ischaemic vascular disease and/or high readings for LDL-C will be approached and asked to participate.
The scientific aims of the study are:
- Identifying individuals with likelihood of FH diagnosis and confirming FH by genetic testing (applying Next Generation Sequencing NGS technology to analyse the genes already known and/or suspected to cause FH).
- Identifying novel FH genes and mutations in the Emirati population by performing whole exome and whole genome sequencing
- Validating positive genetic test results by performing mutational analysis on parental samples (if available)
- Introducing cascade screening on a clinical basis in order to identify affected relatives of those index individuals with a clinical diagnosis of FH
- Determining the prevalence of FH in the UAE
- Determining the short and the long-term clinical outcomes of FH in the UAE
It is expected that the cascade screening will provide additional clinical benefit to study participants and their families in terms of early identification and treatment where diagnosis could otherwise be missed. Early recognition and treatment in individuals with FH has been shown to reduce morbidity and mortality of affected individuals. The information gathered during this project will help introduce a cost-effective method for identifying people with dyslipidaemias and provide early intervention and management.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Genetic Causes of Hypercholesterolaemia in the Emirati Population|
|Actual Study Start Date :||January 17, 2017|
|Estimated Primary Completion Date :||December 31, 2019|
|Estimated Study Completion Date :||December 31, 2019|
Individuals attending Imperial College London Diabetes Centre (ICLDC) and with LDL-C ≥5.0 mmol/L, for children <18 years LDL-C>95th centile by age and gender for country, and possible evidence of known premature CHD.
Individuals with a high probability of disease according to the Dutch Lipid Network Criteria, score of ≥6 points, will be identified as possible probands (individual serving as our starting point for the genetic study of the family) and will be selected for further screening.
Patients will be tested for known and/or suspected FH genes, using next generation sequencing (NGS) panel, whole exome and/or whole genome sequencing (WES/WGS) in cases where FH is highly suspected despite negative results from panel testing, and transcriptomic analysis of RNA blood samples.
Genetic: Next generation sequencing (NGS)
NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
- Next generation sequencing (NGS) [ Time Frame: through study completion, an average of 2 year ]Identify individuals with likelihood of FH diagnosis and confirming FH by genetic testing (applying NGS technology to analyse the genes already known and/or suspected to cause FH).Identifying novel FH genes and mutations in the Emirati population by performing whole exome and whole genome sequencing (WES/WGS).
- Genetic test validation [ Time Frame: through study completion, an average of 2 year ]Validating positive genetic test results by performing mutational analysis on parental samples (if available)
- Cascade screening [ Time Frame: through study completion, an average of 2 year ]Introduce cascade screening on a clinical basis in order to identify affected relatives of those index individuals with a clinical diagnosis of FH
- Prevalence of FH [ Time Frame: through study completion, an average of 2 year ]Determine the prevalence of FH in the UAE
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03597958
|Contact: Hinda Daggag, PhD||+971 2 404 email@example.com|
|United Arab Emirates|
|Imperial College London Diabetes Centre||Recruiting|
|Abu Dhabi, United Arab Emirates, 48338|
|Contact: Hinda Daggag, PhD +971 2 404 0800 firstname.lastname@example.org|
|Principal Investigator:||Maha Barakat, PhD FRCP||Imperial College London Diabetes Centre|